CN 105

Drug Profile

CN 105

Alternative Names: CN-105

Latest Information Update: 14 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CereNova
  • Developer AegisCN
  • Class Anti-inflammatories; Antihaemorrhagics; Apolipoprotein therapeutics; Neuropeptides; Neuroprotectants; Peptides; Small molecules
  • Mechanism of Action Apolipoprotein E agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cerebral haemorrhage

Most Recent Events

  • 01 Aug 2017 Phase-II clinical trials in Cerebral haemorrhage in USA (IV) (NCT03168581)
  • 02 Jun 2017 AegisCN plans a phase II trial for Cerebral haemorrhage in USA (NCT03168581)
  • 01 Aug 2016 CereNova completes phase-I clinical trials in Cerebral haemorrhage (In volunteers) in USA (IV) (NCT02670824)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top